The global medical technology company announced a reassuring update on trading prior to its close period for the year ending 31 December 2009.
The Chairman reported that AMS has had a strong second half of the year and that the Board expects full year earnings to be in line with market expectations.
Sales of its LiquiBand™ topical skin adhesive product has has begun in the US market. Whilst FDA approval is still under review for LiquiBand™ products with specific applications in the operating room, current budgets are covered by the products already approved.
The integration of the Corpura business acquired in October 2009 is also proceeding well.
The fit out of the new facility at Winsford is also proceeding well
A nice story to follow!
